DE60140707D1 - GSK3-Polypeptide - Google Patents

GSK3-Polypeptide

Info

Publication number
DE60140707D1
DE60140707D1 DE60140707T DE60140707T DE60140707D1 DE 60140707 D1 DE60140707 D1 DE 60140707D1 DE 60140707 T DE60140707 T DE 60140707T DE 60140707 T DE60140707 T DE 60140707T DE 60140707 D1 DE60140707 D1 DE 60140707D1
Authority
DE
Germany
Prior art keywords
gsk3
polypeptides
amino acid
substituted amino
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60140707T
Other languages
English (en)
Inventor
Stephen D Harrison
John A Hall
Maria Calderon-Cacia
Ziyang Zhong
Eric Y Fang
Doris G Coit
Steven H Nguyen
Angelica Medina-Selby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE60140707D1 publication Critical patent/DE60140707D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
DE60140707T 2000-07-27 2001-07-25 GSK3-Polypeptide Expired - Lifetime DE60140707D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22124200P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
DE60140707D1 true DE60140707D1 (de) 2010-01-14

Family

ID=22826991

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60131550T Expired - Lifetime DE60131550T2 (de) 2000-07-27 2001-07-25 Gsk3-polypeptide
DE60140707T Expired - Lifetime DE60140707D1 (de) 2000-07-27 2001-07-25 GSK3-Polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60131550T Expired - Lifetime DE60131550T2 (de) 2000-07-27 2001-07-25 Gsk3-polypeptide

Country Status (10)

Country Link
US (6) US6465231B2 (de)
EP (2) EP1319064B1 (de)
JP (1) JP2004504838A (de)
CN (1) CN1276974C (de)
AT (1) ATE450604T1 (de)
AU (1) AU2001280812A1 (de)
DE (2) DE60131550T2 (de)
ES (1) ES2295191T3 (de)
PT (2) PT1914305E (de)
WO (1) WO2002010357A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024893A2 (en) * 2000-09-19 2002-03-28 Chiron Corporation CHARACTERIZATION OF THE GSK-3β PROTEIN AND METHODS OF USE THEREOF
WO2003068932A2 (en) 2002-02-11 2003-08-21 Chiron Corporation Method for crystallizing human gsk3 and novel crystal structure thereof
WO2005083111A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (gsk3a)
WO2006063302A2 (en) * 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
EP1845094A4 (de) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp Verfahren zur tumorsuppression und bewertung von antikrebsmitteln basierend auf einer gsk3-beta-hemmenden wirkung
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
CN101238222B (zh) * 2005-06-20 2013-04-10 解码遗传学私营有限责任公司 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体
US8263139B2 (en) 2005-08-09 2012-09-11 Metaproteonics, Llc Protein kinase modulation by hops and Acacia products
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CA2806734A1 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP3249054A1 (de) 2012-12-20 2017-11-29 Biomatrica, INC. Formulierungen und verfahren zur stabilisierung von pcr-reagenzien
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
BR112018011639A2 (pt) 2015-12-08 2018-11-27 Biomatrica Inc redução de taxa de sedimentação de eritrócitos
CN117384983B (zh) * 2023-12-07 2024-02-23 中国中医科学院中药研究所 一种GSK-3α抑制剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591872A (en) * 1993-08-09 1997-01-07 The University Of Iowa Research Foundation Autoinducer molecule
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5693496A (en) * 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1999061615A1 (en) * 1998-05-28 1999-12-02 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US6057218A (en) * 1999-05-07 2000-05-02 Vanguard International Semiconductor Corporation Method for simultaneously manufacturing poly gate and polycide gate

Also Published As

Publication number Publication date
US6465231B2 (en) 2002-10-15
ES2295191T3 (es) 2008-04-16
US7807430B2 (en) 2010-10-05
WO2002010357A2 (en) 2002-02-07
AU2001280812A1 (en) 2002-02-13
US20030077798A1 (en) 2003-04-24
DE60131550D1 (en) 2008-01-03
US20070249004A1 (en) 2007-10-25
JP2004504838A (ja) 2004-02-19
CN1468302A (zh) 2004-01-14
US7135321B2 (en) 2006-11-14
WO2002010357A3 (en) 2003-04-03
DE60131550T2 (de) 2008-10-23
US6716624B2 (en) 2004-04-06
US20020082408A1 (en) 2002-06-27
PT1319064E (pt) 2008-02-29
US7361484B2 (en) 2008-04-22
ATE450604T1 (de) 2009-12-15
US7195886B2 (en) 2007-03-27
PT1914305E (pt) 2010-01-29
US20080182313A1 (en) 2008-07-31
US20060088932A1 (en) 2006-04-27
EP1319064A2 (de) 2003-06-18
EP1914305B1 (de) 2009-12-02
EP1914305A1 (de) 2008-04-23
EP1319064B1 (de) 2007-11-21
CN1276974C (zh) 2006-09-27
US20050048511A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
ATE450604T1 (de) Gsk3-polypeptide
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
BR0316502A (pt) Compostos quìmicos
DE60311820D1 (de) Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate
DE69422726T2 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
ATE227343T1 (de) Protease und verwandte dns-verbindungen
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200400699A1 (ru) 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины
WO2000034511A3 (de) Peptid screening test zum nachweis von ass
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
DE60118898D1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
BR0112123A (pt) Composto
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
ATE282609T1 (de) Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl) (1,4)diazepan-1-yl)-2- (aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE324881T1 (de) Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen
ATE221882T1 (de) Neue substituierte n-methyl-n-(4-(4-(1h- benzimidazol-2-yl-amino)-piperidin-1-yl)- 2(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
DE50214750D1 (de) Kinase inhibitoren und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1914305

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE